How deadly is Prostate cancer?

['Faalogologo i lenei itulau']

O le ā le mataʻutia o le kanesa o le prostate?

O le kanesa o le prostate o le kanesa lona lua lea e taatele i tamaloloa i le lalolagi atoa, ma le tusa ma le 1.276 miliona mataupu fou na lipotia i le 2018, e fai ma sui o le 7.1% o mataupu uma o le kanesa i alii.

O le fuainumera o tagata ua maliliu i le kanesa o le prostate e maualuga foʻi, ma e tusa ma le 37,005 maliu i le lalolagi atoa i le 2018.

Peitaʻi, e eseese lava le fuainumera o tagata e maliliu i le kanesa o le prostate i atunuu eseese, ma o Aferika i Sisifo e lona lima i le lalolagi i le aofaʻi o tagata e maliliu i le kanesa o le prostate, ae o Nigeria e aupito i toʻatele ona tagata ma e tele foʻi lona tamaoaiga i lea vaipanoa.

I Nigeria, o le kanesa o le prostate o le kanesa lea e sili ona taatele ma e sili ona oti ai tane, ma e tusa ma le 32.8 o tagata e maua ai ma le 16.3 o tagata e maliliu ai i tane e 100,000.

E sili atu i le faaluaina le fuainumera o tagata maliliu i Amerika i Mātū.

O le tuai ona iloa o le faamaʻi, le lē lava o le malosi e faia ai suʻesuʻega ma le lē lelei o le lipotia o faamaʻi, ua māfua ai ona maualuga le maliliu o tagata i Nigeria.

I le Iunaite Setete, o le kanesa o le prostate o le maʻi lona lua lea e māfua ai le oti o tamāloloa i le kanesa, ma e tusa ma le 40,0000 tamāloloa e maliliu i le kanesa i tausaga taʻitasi.

O le kanesa o le prostate ua faasolosolo mālie lava ona faaitiitia le maliliu ai o tagata talu mai le amataga o le 1990, ae o loo avea pea ma faafitauli i le soifua mālōlōina.

I se tulaga lautele, o le kanesa o le prostate o se faamaʻi e oti ai, aemaise lava i vaipanoa e lē tele ai ni togafitiga faafomaʻi ma ni auala e mafai ona iloa ai le kanesa.

Peitaʻi, o le vave iloa ma le vave faia o togafitiga, e mafai ona faaleleia ai le tulaga o le maʻi ma faaitiitia ai le maliliu.

['Faʻamatalaga']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.

Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.

Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.

Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.

Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.

['Faamatalaga: faafomaʻi']

['O lenei upega tafaʻilagi ua saunia mo na o le aʻoaʻoina ma le faailoaina atu o faamatalaga, ae e lē o se fautuaga faafomaʻi po o se auaunaga faapolofesa.']

['E lē tatau ona faaaogā faamatalaga o loo maua mai ai e iloa ai po o le ā le maʻi o loo aafia ai, ma e tatau i ē o loo saʻili mo ni fautuaga faafomaʻi, ona talanoa atu i se fomaʻi ua agavaa.']

['Faamolemole ia mātau, o le neural net lea e maua ai tali i fesili, e lē saʻo pe a oo i fuainumera.']

["Ia saʻili i taimi uma le fautuaga a lau fomaʻi poʻo se isi fomaʻi agavaa e tusa ai ma se maʻi. Aua neʻi e le amanaʻia fautuaga faʻapitoa a fomaʻi pe tuai ona saili ona o se mea na e faitauina i luga o lenei upega tafailagi. Afai e te manatu e ono i ai sau faʻalavelave faʻafuaseʻi, valaʻau le 911 pe alu i le potu lata ane faʻafuaseʻi. E leai se fomaʻi-tagata gasegase sootaga e faia e lenei 'upega tafaʻilagi poʻo lona faʻaaogaina. E leai se BioMedLib poʻo ana tagata faigaluega, poʻo se tasi e fesoasoani i lenei' upega tafaʻilagi, faia ni faʻamatalaga, faʻaalia pe faʻaalia, e tusa ai ma faʻamatalaga o loʻo tuʻuina atu iinei poʻo lona faʻaaogaina."]

['Faʻasalaga: puletaofia']

['O le Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (le DMCA) e maua ai le avanoa mo tagata e umia le puletaofia o loʻo talitonu o mea o loʻo aliali mai i luga o le Initaneti e solia ai a latou aia tatau i lalo o le tulafono a le US copyright. ']

['Afai e te talitonu ma le talitonuga lelei e faapea o so o se mataupu po o meafaitino ua maua e fesootai ma lo tatou website po o auaunaga solia lou puletaofia, e mafai ona e (po o lou sooupu) auina atu i tatou se faasilasilaga talosagaina e faapea o le mataupu po o meafaitino e aveesea, po o le avanoa i ai poloka. ']

['E tatau ona auina atu faasilasilaga i se faiga tusitusia e ala i imeli (tagai i le vaega o le "Contact" mo le tuatusi imeli). ']

['O le DMCA e manaʻomia ai lau faʻasilasilaga o le faʻaleagaina o le puletaofia e aofia ai faʻamatalaga nei: (1) faʻamatalaga o le galuega faʻatagaina o loʻo faʻatatau i le faʻaleagaina o le puletaofia; (2) faʻamatalaga o le mea e ono solia ai ma faʻamatalaga lava e faʻatagaina ai matou ona maua le anotusi; (3) faʻamatalaga faʻafesoʻotaʻi mo oe, e aofia ai lau tuatusi, numera telefoni ma tuatusi imeli; (4) o se faʻamatalaga mai ia te oe o loʻo ia te oe le talitonuga lelei o le anotusi i le auala na faitio ai e le faʻatagaina e le pule o le puletaofia, poʻo lana sooupu, poʻo le faʻatinoina o soʻo se tulafono; ']

['(5) o se faamatalaga mai iā te oe, ua sainia i lalo o le faasalaga o le pepelo, e faapea o faamatalaga o loo i le faasilasilaga e saʻo ma e iai lau pule e faamalosia ai le aiā tatau lea o loo faapea mai ua solia; ']

['ma le (6) saini faaletino po o saini faaeletoroni a lē e ana le aiā tatau po o se tagata ua faatagaina e galue e fai ma sui o lē e ana le aiā tatau. ']

['Afai e lē o aofia uma faamatalaga o loo i luga, e ono faatuai ai ona iloilo lau faitioga.']

['Faafesootaʻi']

['Faamolemole lafo mai se imeli i so o se fesili / fautuaga.']

How deadly is prostate cancer?

Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.

The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.

However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.

In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.

This is more than double the death rate in North America.

Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.

In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.

The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.

Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.

However, early detection and treatment can significantly improve outcomes and reduce mortality rates.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.